Software

You may have missed

OMass Therapeutics Adds Mark Namchuk, PhD to Scientific Advisory Board

Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review

Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review

Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe

NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy

error: Content is protected !!